• 1. An intramolecular tryptophan-condensation approach for peptide stapling?
  Eunice Y.-L. Hui,Bhimsen Rout,Yaw Sing Tan,Kok-Ping Chan,Charles W. Johannes Org. Biomol. Chem., 2018,16, 389-392
• 2. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 3. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 4. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 5. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere

D-2’-Deoxyribofuranosyl-3-guanylurea(a/b-Mixture) (CAS No: 570410-72-9) in Modern Chemical and Biomedical Research

The compound D-2’-Deoxyribofuranosyl-3-guanylurea(a/b-Mixture), identified by its CAS number 570410-72-9, represents a fascinating molecule with significant implications in the realms of chemical biology and pharmaceutical innovation. This glycosylated guanidine derivative has garnered attention due to its unique structural features and potential applications in drug design, particularly in the development of nucleoside analogs and enzyme inhibitors. The (a/b-Mixture) designation suggests a complex isomeric composition, which further enhances its structural diversity and functional versatility.

In recent years, the study of nucleoside analogs has been pivotal in the fight against various viral and bacterial infections. The core structure of D-2’-Deoxyribofuranosyl-3-guanylurea(a/b-Mixture) shares similarities with natural nucleosides, making it a promising candidate for developing antiviral agents. Specifically, its guanidine moiety can interact with biological targets such as enzymes and receptors, while the modified sugar moiety provides stability against degradation by nucleases. This balance of structural mimicry and chemical robustness has positioned this compound as a subject of intense research interest.

One of the most compelling aspects of D-2’-Deoxyribofuranosyl-3-guanylurea(a/b-Mixture) is its potential in inhibiting key enzymes involved in pathogenic processes. For instance, researchers have explored its efficacy in targeting RNA-dependent RNA polymerases (RdRp) in viruses like influenza and hepatitis C. The guanidine group can act as a hydrogen bond acceptor, mimicking the natural base pairing interactions within the enzyme's active site. This interaction can lead to competitive inhibition, effectively halting viral replication. Preliminary studies have shown promising results in vitro, suggesting that further investigation could yield novel therapeutic strategies.

The (a/b-Mixture) form of this compound adds another layer of complexity, as it likely encompasses multiple stereoisomers that could exhibit varying biological activities. Isomerism in glycosylated compounds is well-documented to influence both metabolic stability and pharmacokinetic properties. By studying the (a/b-Mixture), researchers can gain insights into how different stereoisomers contribute to overall activity, potentially leading to more refined drug candidates. Techniques such as chromatography and spectroscopy are employed to isolate and characterize these isomers, ensuring that each component's role is fully understood.

Beyond antiviral applications, D-2’-Deoxyribofuranosyl-3-guanylurea(a/b-Mixture) has shown promise in other therapeutic areas. Its structural motif is reminiscent of known anticancer agents, where modifications at the sugar or guanidine positions can enhance binding affinity to target proteins. For example, studies have investigated its potential as an inhibitor of kinases involved in tumor growth and progression. The ability to fine-tune the structure for optimal binding without compromising solubility or bioavailability remains a key challenge in medicinal chemistry.

The synthesis of such complex molecules requires meticulous planning and advanced synthetic methodologies. The introduction of the urea linkage at the 3-position adds a significant synthetic challenge, as it must be introduced without disrupting sensitive functional groups elsewhere on the molecule. Modern techniques like solid-phase synthesis and flow chemistry have enabled more efficient production scales while maintaining high purity standards. These advancements are crucial for translating laboratory findings into viable drug candidates.

In conclusion, D-2’-Deoxyribofuranosyl-3-guanylurea(a/b-Mixture) (CAS No: 570410-72-9) stands out as a versatile compound with broad applications in chemical biology and pharmaceutical research. Its unique structural features make it an attractive scaffold for developing antiviral and anticancer agents. The complexity introduced by its (a/b-Mixture) form offers opportunities for exploring multiple biological pathways simultaneously. As research continues to uncover new therapeutic targets and synthetic strategies, this compound will undoubtedly play a significant role in shaping future treatments for various diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)